857283-88-6

Basic information

• Product Name: 6-MORPHOLINOPYRIDINE-2-CARBALDEHYDE
• Synonyms: 6-MORPHOLINOPYRIDINE-2-CARBALDEHYDE;6-MORPHOLINOPYRIDINE-2-CARBOXALDEHYDE;6-Morpholin-4-ylpyridine-2-carboxaldehyde;6-Morpholin-4-ylpyridine-2-carboxaldehyde 97%;4-(6-Formylpyridin-2-yl)morpholine;6-Morpholinopicolinaldehyde;6-Morpholin-4-ylpyridine-2-carbaldehyde;4-(6-Formylpyridin-2-yl)morpholine, 2-Formyl-6-(morpholin-4-yl)pyridine
• CAS NO: 857283-88-6
• Molecular Formula: C₁₀H₁₂N₂O₂
• Molecular Weight: 192.21
• Mol File: 857283-88-6.mol
• Article Data: 4

Chemical Properties

• Melting Point: 93 °C
• Boiling Point: 366.4°C at 760 mmHg
• Flash Point: 175.4°C
• Appearance: /
• Density: 1.219g/cm³
• Vapor Pressure: 1.47E-05mmHg at 25°C
• Refractive Index: 1.586
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-MORPHOLINOPYRIDINE-2-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-MORPHOLINOPYRIDINE-2-CARBALDEHYDE(857283-88-6)
• EPA Substance Registry System: 6-MORPHOLINOPYRIDINE-2-CARBALDEHYDE(857283-88-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 857283-88-6(Hazardous Substances Data)

Usage

General Description

6-Morpholinopyridine-2-carbaldehyde is a chemical compound with the molecular formula C8H10N2O2. It is a derivative of pyridine and contains a morpholine ring and a carbaldehyde group. 6-MORPHOLINOPYRIDINE-2-CARBALDEHYDE is commonly used as a reagent in organic synthesis and as a building block in the production of pharmaceuticals and agrochemicals. It is known for its ability to participate in various chemical reactions, such as the formation of heterocyclic compounds and the synthesis of biologically active molecules. Additionally, 6-morpholinopyridine-2-carbaldehyde has been investigated for its potential use in the development of new drugs and as a ligand in coordination chemistry.

InChI:InChI=1/C10H12N2O2/c13-8-9-2-1-3-10(11-9)12-4-6-14-7-5-12/h1-3,8H,4-7H2

Upstream product

• 110-91-8 morpholine 
• 34160-40-2 6-bromo-2-pyridinecarbaldehyde 
• 34199-87-6 6-bromo-2-(1,3-dioxolan-2-yl)pyridine 

Downstream Products

• 867167-62-2 1-(4-amino-phenyl)-3-(6-morpholin-4-yl-pyridin-2-yl)-propenone 
• 867167-14-4 4-[3-(6-morpholin-4-yl-pyridin-2-yl)-acryloyl]-benzoic acid 
• 1062205-13-3 [3-(6-morpholin-4-yl-9-{1-[(6-morpholin-4-ylpyridin-2-yl)methyl]piperidin-4-yl}-9H-purin-2-yl)phenyl]methanol 
• 1096165-35-3 1-benzyl-3,3-dimethyl-5-[1-(6-morpholin-4-yl-pyridin-2-yl)-methylidene]-piperidin-4-one 
• 1096166-20-9 1-benzyl-3-[1-(6-morpholin-4-yl-pyridin-2-yl)-methylidene]-5-phenyl-piperidine-2,4-dione 

Relevant articles and documents

CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF

Provided are compounds of formula (Ia), (Ib) and (IIa), and pharmaceutically acceptable salts thereof. Additionally provided are compositions and pharmaceutical compositions comprising the compounds, therapeutic methods using same for modulating (e.g., inhibiting) CREB binding protein (CBP)/β-catenin mediated signaling in treating a condition, disease or disorder (e.g., fibrosis, cancer, neurological conditions, metabolic disorders (e.g., diabetes, etc.), and skin conditions (dermatitis, psoriasis, scarring, alopecia, etc.) mediated by aberrant CBP/β -catenin signaling, and cosmetic methods for treating skin conditions (e.g., aging, etc.). Additionally provided are methods for enhancing vaccine efficacy using the compounds and compositions. Further provided are methods for efficiently synthesizing a clinical grade drug, comprising use, in a penultimate, or last reaction step under GMP conditions, of an intermediate 2-propynyl-compound to form a clinical grade isoxazole derivative (e.g., via 3+2 cycloaddition).

NOVEL SUBSTITUTED PIPERIDONES AS HSP INDUCERS

The present invention relates to novel compounds of formula (I) or (II), their pharmaceutically acceptable salts and their hydrates, solvates, stereoisomers, conformers, tautomers, polymorphs and prodrugs and also pharmaceutically acceptable compositions containing them Wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification. The compounds of the present invention are HSP inducers and by virtue of this effect, useful for the treatment of various diseases accompanying pathological stress. The present invention also relates to a process for the preparation of the said novel compounds. The invention also relates to the use of the above-mentioned compounds for the preparation of medicament for use as pharmaceuticals.